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Isolated nodal failure after chemo-radio-
therapy in limited disease small cell lung 
cancer (LD-SCLC)
Marek WIERZCHOWSKI, Arkadiusz SPRAWKA, Lucyna KĘPKA
ABSTRACT
BACKGROUND: The irradiation volume for treatment of limited disease small cell lung cancer (LD-
SCLC), are still controversial. One of the aspects of radiation volume is the use of elective nodal irradia-
tion (ENI), which has never been subjected to randomized study in SCLC patients. 
AIM: To review retrospectively patterns of failure in relation to the radiation fi eld after chemoradio-
therapy (CHT-RT) in patients with limited disease small cell lung cancer (LD-SCLC).
MATERIAL AND METHODS: Between 1997 and 2006, 117 consecutive patients with LD-SCLC received 
chemotherapy with sequential radiotherapy (70%) and concurrent or alternating CHT-RT (30%). All 
but one case had predefi ned elective nodal irradiation (ENI) without inclusion of supraclavicular re-
gions. Prophylactic cranial irradiation (PCI) was administered to 39% of patients.
RESULTS: The median follow-up for the 20 living patients was 33 months. The overall survival at 2 
years was 36% (median survival: 18 months). In-fi eld locoregional progression was observed in 42 pa-
tients (36%). Distant metastases occurred in 71 patients (61%). Five patients (4%) developed isolated 
nodal failure (INF) without local progression in the supraclavicular region. Patients with INF had N3 
disease more often than those without INF (60% vs 21%, p = 0.04). There was 5% RTOG grade 3 or 
higher early radiation toxicity.
CONCLUSIONS: INF failures are rare; however, the need for extension of ENI to supraclavicular areas 
may be reconsidered in N3 patients.
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BACKGROUND
The benefi t of using radiotherapy (RT) for 
limited disease small cell lung cancer (LD-
SCLC) was shown by two meta-analyses [1, 2] 
in 1992 and its use has not raised major con-
troversies since then. However, many topics 
related to RT for LD-SCLC, such as the timing 
of its use in relation to chemotherapy (CHT), 
fractionation schedule, total dose, and irra-
diation volumes, are still controversial and 
involve unresolved issues. Since timing, frac-
tionation, and dose have been subject to many 
prospective trials, we can draw a number of 
conclusions from these studies and guide our 
clinical practice by the results of these trials, 
even if there is still some debate on these is-
sues. On the other hand, radiation target vol-
ume has not been evaluated in prospective 
studies, apart from one pre-CT-era study in 
which patients with partial response after 
CHT were randomized to treatment by the 
use of portals including pre-CHT or post-CHT 
images on chest X-rays. Although there was 
no difference in the rate of local recurrences 
in the respective treatment arms according to 
pre- and post-CHT volumes [3], we probably 
cannot rely on the fi ndings of a study based 
on, from a contemporary point of view, poor 
imaging. The other aspect of radiation volume 
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is the use of elective nodal irradiation (ENI), 
which has never been subjected to random-
ized study in SCLC patients. Despite the lack 
of evidence on the safety and/or benefi t of the 
omission of ENI, the two current randomized 
trials on RT in LD-SCLC (one in its fi nal ap-
proval stage by a major North American col-
laborative group and one recently launched by 
EORTC) do not allow for any form of ENI [4]. 
As our departmental policy has always been 
to use some ENI for LD-SCLC, the question 
has arisen as to whether we should also limit 
the radiation portals to the involved fi elds. 
AIM
To review retrospectively patterns of failure 
in relation to the radiation fi eld after chemora-
diotherapy (CHT-RT) in patients with limited 
disease small cell lung cancer (LD-SCLC).
PATIENTS AND METHODS
Patients
A review of the database in the Department of 
Radiation Oncology of the Maria Sklodowska-
Curie Memorial Cancer Center and Institute 
of Oncology in Warsaw identifi ed 117 consecu-
tive patients who completed radical thoracic 
radiotherapy as part of initial treatment for 
LD-SCLC between 1997 and 2006. Medi-
cal records of all patients were available for 
review. The characteristics of the group are 
given in Table 1.
The departmental policy was to perform 
bronchoscopy, chest CT with inclusion of up-
per abdomen, brain CT or MRI and bone scan 
as obligatory components of initial staging for 
establishing a diagnosis of LD-SCLC. Bone 
marrow aspiration/biopsy was not manda-
tory in the later part of the period of interest. 
Despite these guidelines, the chart review 
showed that 20% of patients had no brain im-
aging, 35% had no bone scan, and 70% had no 
bone marrow aspiration/biopsy done for ini-
tial staging. 
Follow-up visits started one month after 
treatment completion, and then were per-
formed every three months. These visits in-
volved clinical examinations, chest X-rays, 
and basic blood examinations; chest CT scans 
were performed one and six months after RT 
and thereafter annually or more frequently 
if disease progression was suspected. Other 
examinations were performed if metastases 
were clinically suspected. Bronchoscopy and 
pulmonary function tests were performed 
when needed for clinical purposes.
Treatment characteristics
Chemotherapy consisted of 2–6 (median: 4) 
courses of cisplatin and etoposide (PE) every 
21 days; however 18 (15%) patients received 
another type of CHT due to toxicity or other 
reasons, as listed in Table 2. Sequential treat-
ment was given to 82 (70%) patients. The total 
dose of sequential RT varied from 44 Gy to 60 
Gy (median: 56 Gy), with 2 Gy per fraction. 
Seventeen (15%) patients were treated with a 
concurrent schedule with hyperfractionation, 
Characteristics Number (%) unless 
otherwise stated
Sex
Male 73 (62%)
Female 44 (38%)
Age Median: 57 (Range: 43 – 78)
WHO Performance status 
0 87 (74%)
I 29 (25%)
II 1 (1%)
Weight loss (%)
0 96 (82%)
1-5 11 (9%)
6-10 7 (6%)
>10 3 (3%)
Tumor Main Site
Upper lobe 50 (43%)
Middle or lower lobe 67 (57%)
Nodal involvement
N0 20 (17%)
N1 11 (9%)
N2 51 (44%)
N3 24 (21%)
No exact data 11 (9%)
Presence of Bulky Mediastinal Disease 70 (60%)
Upper mediastinum involvement 23 (20%)
Table 1. Characteristics of patients 
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with a regimen of 30 x 1.5 Gy twice daily given 
with the fi rst of four cycles of PE. The alter-
nating schedule was used in 18 (15%) patients 
and consisted of a combination of four courses 
of PE divided by three courses of RT of 20 Gy, 
20 Gy, and 16 Gy, respectively, with 2 Gy per 
fraction. The assignment to the type of CHT-
RT combination refl ected changes in depart-
mental treatment policy over time, but as a 
rule, patients who were fi tter and with smaller 
tumour volumes were given concurrent treat-
ment. Prophylactic cranial irradiation (PCI) 
was administered to 39% of patients. The total 
dose of PCI varied between 10 Gy (one patient) 
and 30 Gy (median: 25 Gy) with a dose per 
fraction of 1.8 to 3 Gy (median 2.5 Gy).
For 52% of patients, the elective fi elds were 
2D planned using anterior–posterior/posteri-
or–anterior (AP/PA) fi elds and treated up to 
44 Gy in the conventional fractionation group, 
and up to 30 Gy in the hyperfractionated sched-
ule. The oblique fi elds were consecutively 3D 
planned for boost and treated up to a median of 
56 Gy in the conventional arm and 45 Gy in the 
cases treated twice daily. For the remaining 
48% of patients, the total course of radiothera-
py (elective and boost fi elds) was 3D planned. 
Two-D techniques were used before routine 
introduction of the entire 3D planning for lung 
cancer patients in our department. The boost 
volumes were defi ned as macroscopic tumour 
and pathologic mediastinal/hilar (rarely, su-
praclavicular) lymph nodes (with short axis 
diameter larger than 1 cm in CT) with a 1–2 
cm margin. The elective area encompassed 
the bilateral mediastinal and ipsilateral hilar 
lymph nodes. Supraclavicular regions were 
not electively treated, except in one case. The 
superior border of the elective fi eld was set at 
the sternal notch. The inferior border was set 
5 cm under the carina for upper lobe tumours 
Table 2. Chemotherapy schedules used
Regimen Number of patients (%)
PE cisplatin with etoposide 100 (85%)
KE karboplatin with etoposide 6 (5%)
CAV (Cyclofosfamide, Doxorubicin, 
Vincristine)
1 (1%)
Other (mostly combinations 
of above)
10 (9%)
and at the diaphragm for lower/middle lobe 
tumours. The lateral borders were set at 1 
cm from the mediastinal shadow. 3D-planned 
elective fi elds were mainly also AP/PA-orient-
ed and their borders did not vary signifi cantly 
from the 2D-planned fi elds, as attention was 
paid to keeping the same anatomical land-
marks as for the borders in 2D-planned ENI 
fi elds. The general departmental policy was 
to include in the radiation fi eld the pre-CHT 
involved lymph node stations regardless of 
the CHT response, and decisions regarding 
inclusion in the fi eld of pre-CHT volumes of 
tumours located within the pulmonary paren-
chyma were left to the discretion of the treat-
ing physician. In cases of massive initial lung 
involvement and/or poor pulmonary function, 
the radiation volume did not include the entire 
pre-CHT involved lung.
Analysis of sites of failure
The sites of failure were defi ned based on 
medical record review. If doubt on the occur-
rence or location of relapse arose, the radio-
logical imaging and radiation planning data 
were reviewed. Locoregional relapse was de-
fi ned as progression of the primary tumour or 
initially involved lymph nodes, whichever oc-
curred fi rst. Isolated nodal failure (INF) was 
defi ned as a regional nodal failure occurring 
without locoregional progression. Whether or 
not the location of the INF was included in a 
radiation fi eld was recorded.
Statistical analysis
The overall survival and disease-free survival 
were assessed using the Kaplan–Meier meth-
od. The log-rank test was used to fi nd any re-
lationships between outcomes and treatment 
parameters. For the occurrence of INF, the 
infl uence of tumour-related parameters such 
as the location of the tumour, the N stage, the 
involvement of the upper mediastinum and the 
presence of bulky mediastinal disease (BMD) 
were sought by proportion comparisons us-
ing the chi-square test in a 2 x 2 contingency 
table format. BMD was defi ned as the initial 
involvement of at least three lymph node sta-
tions within the mediastinum and/or an in-
crease in the size of a single lymph node to at 
least 3 cm. SPSS software (Statistical Package 
for the Social Sciences) for Windows (version 
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14; SPSS, Chicago Illinois, USA) was used for 
statistical analysis.
RESULTS
Median follow-up for the 20 censored patients 
was 33 months. The overall survival rates at 2 
and 3 years were 36% and 26%, respectively, 
and median survival was 18 months. The dis-
ease-free survival rates at 2 and 3 years were 
17% and 15%, respectively. The overall sur-
vival at 2 years was 29% for patients treated 
with sequential treatment and 49% for those 
with concurrent and alternating schedules 
(p = 0.28). There was no difference in 2-year 
overall survival with respect to PCI use (41% 
PCI vs 33% without PCI, p = 0.23). There was 
no difference in 2-year overall survival with 
respect to the technique of radiotherapy used 
(29% for 2D technique vs 43% for 3D tech-
nique, p = 0.14).
Locoregional progression was observed 
in 42 (36%) patients. Distant recurrence oc-
curred in 71 patients (61%). It is noteworthy 
that 41 (35%) had brain metastases, 21 (18%) 
with isolated brain metastases. Only fi ve (11%) 
patients developed isolated brain metastases 
in the PCI group. There was a statistically 
signifi cant difference in the cumulative inci-
dence of brain metastases with respect to PCI 
use (50% vs 16% at 2 years for no PCI vs PCI, 
p = 0.003).
Five (4%) patients developed INF. All de-
tected cases of INF were localized in the su-
praclavicular region and were out-of-fi eld fail-
ures. The nodal stages of this selected group 
with occurrence of INF were N1 – one patient, 
N2 – one patient, and N3 – three patients. Pa-
tients with an N3 nodal stage accounted for 
60% of the fi ve patients with INF, compared 
with 21% of 101 without INF with known N 
stage (p = 0.04). Four of fi ve cases (80%) with 
INF had BMD at the initial staging in compari-
son with 66 (59%) in the remainder (p = 0.34). 
Two of fi ve patients (40%) with INF had the 
primary tumour localized in the upper lobe, 
in comparison with 48 (43%) in the remainder 
(p = 0.90). Two (40%) of the INF cases had 
initial involvement of the upper mediastinum 
in comparison with 21 (19%) patients without 
occurrence of INF (p = 0.24). Median time to 
INF occurrence was 9.5 months (range: 8–17 
months). Median survival of patients from the 
diagnosis of INF was 4 months (range 2–50 
months).
The retrospectively evaluated toxicity was 
mild, with only 5% RTOG grade 3 or higher 
radiation-induced toxicity (one toxicity-relat-
ed death).
DISCUSSION
We have identifi ed distant metastases as the 
most common type of failure after combined 
treatment of LD-SCLC, with 35% local re-
lapses, which is in agreement with other data 
[5, 6]. The frequency of isolated nodal failure 
following thoracic radiotherapy for this dis-
ease has rarely been the subject of investiga-
tion. Studies from the pre-CT era suggested 
that violations in protocols related to incom-
plete coverage of the predefi ned large elective 
area, including the bilateral mediastinum and 
hila, as well as the bilateral supraclavicular 
regions, led to excessive locoregional relapse 
rates and shortened survival [7]. However, 
such fi ndings must be interpreted with refer-
ence to the inadequate diagnostic techniques 
and the high probability of the geographic 
mistargeting of gross disease. In the CT era, 
Tada et al. [8] have shown a 16% rate of mar-
ginal (at the edge and out-of-fi eld) failure in 
117 patients managed with RT-CHT. When we 
exclude from the marginal failures three cer-
vical metastases and fi ve others in the periph-
eral lung, we obtain 11 “true” marginal nodal 
failures, which gives a 9% isolated nodal fail-
ure rate. This is more than in our retrospec-
tive study; however, our approach to elective 
treatment was stricter, rendering our elec-
tive fi elds more extensive than in the study by 
Tada et al. [8]. We have adopted a fi eld design 
as described by Turrisi et al. [9], treating the 
bilateral mediastinum and ipsilateral hilum, 
without supraclavicular nodes if not involved, 
following what was a quite general policy in 
most trials beginning in the 1990s [4]. Our 
policy resulted in a 4% isolated nodal failure 
rate, all in the supraclavicular area and out-
side the radiation fi eld. This is less than in 
the study of Tada et al., which did not have 
a strict approach to elective fi eld design, and 
less than the 11% supraclavicular nodal fail-
ures seen in the short follow-up period of a 
prospective phase II study with the omission 
of ENI for LD-SCLC [10]. In contrast to those 
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fi ndings, Baas et al. [11] did not observe any 
isolated nodal failures in 37 patients treated 
with concurrent CHT-RT without ENI. The 
observed difference in the rate of isolated 
nodal failures localized to the supraclavicular 
region between these studies with omission of 
ENI may be related to very meticulous patient 
staging before treatment in the study of Baas 
et al. [11], in contrast to the study of De Ruys-
scher et al. [10], which was based on evalua-
tion of the supraclavicular areas by CT only. 
As indicated by Belderbos [12], in comparison 
with CT alone, the evaluation of the supra-
clavicular area with at least ultrasound, in the 
absence of PET, may improve the diagnosis of 
supraclavicular nodes. Improved staging may 
improve radiation planning for LD-SCLC; 
however, the role of tools such as 18FDG-PET 
is still under investigation in this disease and 
requires more data before their routine imple-
mentation [4, 13, 14].
The low rate of isolated nodal failures re-
ported after RT for LD-SCLC, with an ap-
proximately 30%–50% rate of local relapse 
[5], prompted some investigators to shift to 
a higher radiation dose to the involved fi elds 
or more aggressive chemotherapy (without 
ENI), in view of improvements in the thera-
peutic ratio [4]. However, the failure rate of 
about 5% is not negligible, as all isolated nodal 
failures ultimately failed salvage therapy, as 
shown in our study. This led to the worsen-
ing of outcome in about 5%, equal to the ben-
efi t resulting from the use of thoracic therapy 
or PCI, which was a reason for the common 
implementation of these treatment strategies. 
We have no evidence that the omission of ENI 
in LD-SCLC may reduce toxicity, since in 
the two prospective studies with omission of 
ENI, the toxicity was quite high and was not 
reduced in comparison with historical series 
[10, 11]. We observed an exceptionally low rate 
of early toxicity in our study, but this was re-
lated to the mostly sequential schedule of de-
livering CHT-RT and very careful selection of 
patients for the concurrent combination. The 
retrospective character of the study may also 
underestimate the incidence of toxic events. 
We tried to defi ne the characteristics of 
patients with isolated nodal failures. Tada et 
al. [8] found that a higher nodal stage was 
related to a higher risk of isolated nodal fail-
ure. A similar observation was made for non-
small cell lung cancer (NSCLC) in the study of 
Kepka et al. [15]. Therefore, we looked for any 
relationship between initial nodal characteris-
tics and the risk of isolated nodal failures. The 
small number of events may compromise any 
statistical considerations; however, N3 disease 
reached statistical signifi cance, as it did in the 
study of Tada et al. [8]. The presence of bulky 
mediastinal disease as well as the involvement 
of the upper mediastinum may also infl uence 
the incidence of supraclavicular failures in 
the absence of irradiation of this area. As the 
toxicity of ENI is not proven in clinical stud-
ies, enlargement of the radiation fi eld to the 
supraclavicular region is unlikely to increase 
toxicity, especially if large portals for upper 
mediastinum involvement and/or treatment 
of bulky mediastinum are already employed. 
Taking into account the results of this study 
and our previous work on the risk of out-of-
fi eld failure for NSCLC [15], we have started 
a planning study to examine the infl uence of 
enlargement of the fi eld to the supraclavicular 
area on doses to critical structures, especially 
the oesophagus and lung, in cases of extensive 
nodal involvement in terms of stage, number, 
and/or location.
CONCLUSIONS
INF failures are rare; however, the need for 
extension of ENI to supraclavicular areas may 
be reconsidered in a more advanced nodal 
stage.
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